Semaglutide has been approved for reducing the risk of major adverse cardiovascular events in patients with obesity and heart disease, as well as for preventing the progression of kidney disease in individuals with type 2 diabetes and chronic kidney disease
As most GLP-1RAs need to be frequently administered subcutaneously (once weekly, once daily or even twice daily), their long-term usage can cause injection-site-related events (Madsbad, 2016
In clinical trials, Semaglutide has been shown to effectively reduce body weight and improve glycemic control in individuals with obesity and type 2 diabetes
GLP-1 slows down the digestion process
De la misma forma, es importante beber abundante agua para la eliminacin de esas grasas y toxinas presentes en el organismo
Some patients pair the injection with a consistent weekly routine (Sunday evening before the work week, for example) to reduce the chance of forgetting